硼替佐米联合大剂量美法仑预处理方案用于初治多发性骨髓瘤:一项IFM随机3期研究
该随机3期研究纳入300例适合移植的初治多发性骨髓瘤患者,比较硼替佐米联合大剂量美法仑(Bor-HDM)与单用大剂量美法仑(HDM)的疗效与安全性。主要终点移植后第60天严格完全缓解+完全缓解率两组无差异(22.1% vs 20.5%,P=.844),微小残留病不可检测率、无进展生存期和总生存期均无显著差异。Bor-HDM组严重不良事件发生率为18.7%,3/4级或疼痛性周围神经病变发生率为4%。
要点
- Bor-HDM与HDM相比,移植后第60天严格完全缓解+完全缓解率无显著差异(22.1% vs 20.5%,P=.844)。
- 中位无进展生存期两组无显著差异(34.0个月 vs 29.6个月,校正HR 0.82,95%CI 0.61-1.13,P=.244)。
- Bor-HDM组3/4级或疼痛性周围神经病变发生率为4%,高于HDM组的1.5%。
核心结论
- 在适合移植的初治多发性骨髓瘤患者中,硼替佐米联合大剂量美法仑预处理方案与单用大剂量美法仑相比,未改善疗效终点或结局。
研究设计与样本
- 随机3期研究,纳入300例适合移植的初治多发性骨髓瘤患者,按风险和诱导治疗反应分层随机。
- 实验组(A组)154例接受硼替佐米(1 mg/m2静脉注射,第-6、-3、+1、+4天)联合美法仑(200 mg/m2静脉注射,第-2天);对照组(B组)接受单用美法仑(200 mg/m2静脉注射)。
主要发现
- 移植后第60天严格完全缓解+完全缓解率:A组22.1% vs B组20.5%(P=.844)。
- 微小残留病不可检测率:A组41.3% vs B组39.4%(P=.864)。
- 中位无进展生存期:A组34.0个月 vs B组29.6个月(校正HR 0.82,95%CI 0.61-1.13,P=.244)。
- 估计3年总生存率两组均为89.5%(HR 1.28,95%CI 0.62-2.64,P=.374)。
- 严重不良事件发生率:Bor-HDM组18.7% vs HDM组13.1%;3/4级不良事件比例两组相似(72.0% vs 73.1%),主要为血液和胃肠道疾病;3/4级或疼痛性周围神经病变发生率A组4% vs B组1.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safely and effectively be combined with HDM (Bor-HDM), with a 32% complete response (CR) rate after transplantation. These data supported a randomized phase 3 trial. Randomization was stratified according to risk and response to induction: 300 patients were enrolled, and 154 were allocated to the experimental arm (ie, arm A) with bortezomib (1 mg/m2 intravenously [IV]) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2. The control arm (ie, arm B) consisted of HDM alone (200 mg/m2 IV). There were no differences in stringent CR + CR rates at day 60 posttransplant (primary end point): 22.1% in arm A vs 20.5% in arm B (P = .844). There were also no differences in undetectable minimum residual disease rates: 41.3% vs 39.4% (P = .864). Median progression-free survival was 34.0 months for arm A vs 29.6 months for arm B (adjusted HR, 0.82; 95% CI, 0.61-1.13; P = .244). The estimated 3-year overall survival was 89.5% in both arms (hazard ratio, 1.28; 95% CI, 0.62-2.64; P = .374). Sixty-nine serious adverse events occurred in 18.7% of Bor-HDM-treated patients (vs 13.1% in HDM-treated patients). The proportion of grade 3/4 AEs was similar within the 2 groups (72.0% vs 73.1%), mainly (as expected) blood and gastrointestinal disorders; 4% of patients reported grade 3/4 or painful peripheral neuropathy in arm A (vs 1.5% in arm B). In this randomized phase 3 study, a conditioning regimen with Bor-HDM did not improve efficacy end points or outcomes compared with HDM alone. The original trial was registered at www.clinicaltrials.gov as #NCT02197221.
引用
- Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022. PMID: 35511184. doi:10.1182/blood.2021014635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。